Aztiq announces the recent establishment of a new entity Arphio a venture initiated in close collaboration with SK Pharma.
Together with SK Pharma, Aztiq, is developing a powerhouse, solely dedicated to orphan drugs with the intention of improving accessibility of vital treatments, to patients suffering from rare diseases and unmet medical needs.
Arphio will operate as an independent entity, focusing on rare disease detection, market access and supply of orphan drugs, targeting the EU and ROW regions. Arphio has a unique understanding on orphan products and their epidemiology data and unique characteristics. The aim of this venture is to expand access to vital treatments and continue to develop technological capabilities and expertise, while maintaining a patient-centric approach with the possibility of relying on state-of-the art novel technology including worldwide data, artificial intelligence and machine learning.
This stand-alone market player, will cover all services and functions ranging from medical, market access, regulatory, direct sales and marketing activities. Arphio proudly boasts of strictly following ethics, compliance, accessibility and corporate governance.
There are over 300 million people living with one or more of over 7,000 identified rare diseases around the world, each supported by family, friends and caregivers. Currently, only about 5% of orphan disorders can be managed with an approved treatment. It is estimated that it takes about seven years and visits to 10 different doctors for a patient to receive a proper diagnostic of an orphan condition. At Arphio , fueled by our passion to improve people’s lives, we will apply innovative technologies to provide effective treatments for people with orphan diseases.
Anil Okay, Partner at Aztiq comments: “We are thrilled to be partnering with SK Pharma on this exciting new journey. We welcome this opportunity to work in the domain of Orphan drugs, and we are eager to make a valuable contribution to patients across the globe who are living with Rare diseases”.
Dr. Shlomo Sadoun, CEO at SK Pharma comments: “I’m captivated to have Adalvo as our partner with the important endeavor of helping neglected orphan patients and their caregivers with their unmet medical needs. I’m bullish on the synergistical power that could outcome from this collaboration for the benefit of rare disease patients"